1
|
Zhao Y, Tang C, Huang J, Zhang H, Shi J, Xu S, Ma L, Peng C, Liu Q, Xiong Y. Screening Multidrug Resistance Reversal Agents in Traditional Chinese Medicines by Efflux Kinetics of D-Luciferin in MCF-7/DOX Fluc Cells. ACS OMEGA 2023; 8:4853-4861. [PMID: 36777569 PMCID: PMC9909823 DOI: 10.1021/acsomega.2c07096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Accepted: 01/05/2023] [Indexed: 06/18/2023]
Abstract
In this study, we established a simple and rapid in vitro method for screening multidrug resistance (MDR) reversal agents in traditional Chinese medicines (TCMs), which could better correspond to the MDR reversing effect in vivo. Here, D-luciferin, a substrate for the enzyme firefly luciferase and also a substrate for ATP-binding cassette transporters (ABC transporters), was used as the probe to detect its efflux kinetics caused by ABC transporters. First, we established a stable doxorubicin (DOX)-resistant cell line (MCF-7/DOXFluc) that overexpressed luciferase. Then, some kinds of TCMs were chosen for the MDR reversal agents to measure its effect on inhibiting the D-luciferin outflow from MCF-7/DOXFluc, and the ideal reversal agent with the least D-luciferin efflux from MCF-7/DOXFluc was selected to further investigate its effect combined with DOX on MCF-7/DOXFluc tumor-bearing mice. The results indicated that quercetin (Qu) could remarkably increase the retention of D-luciferin in MCF-7/DOXFluc in vitro and in vivo. Also, the combination of Qu and DOX could exceedingly inhibit the tumor growth, which proved the feasibility of this in vitro screening method. The study proposed a feasible method for mass screening of MDR agents from TCMs in vitro.
Collapse
Affiliation(s)
- Yue Zhao
- College
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou, Zhejiang 311258, China
- Academy
of Chinese Medical Science, Zhejiang Chinese
Medical University, Hangzhou, Zhejiang 311258, China
| | - Chaoyuan Tang
- College
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou, Zhejiang 311258, China
- Changxing
People’s Hospital of Zhejiang, Huzhou, Zhejiang 313100, China
| | - Jingyi Huang
- College
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou, Zhejiang 311258, China
| | - Hongyan Zhang
- College
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou, Zhejiang 311258, China
| | - Jingbin Shi
- College
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou, Zhejiang 311258, China
| | - Shujun Xu
- College
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou, Zhejiang 311258, China
| | - Lisha Ma
- College
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou, Zhejiang 311258, China
| | - Chun Peng
- School
of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China
| | - Qi Liu
- Department
of Dermatology, Johns Hopkins University
School of Medicine, Baltimore, Maryland 21231, United States
| | - Yang Xiong
- College
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou, Zhejiang 311258, China
- Academy
of Chinese Medical Science, Zhejiang Chinese
Medical University, Hangzhou, Zhejiang 311258, China
| |
Collapse
|
2
|
Qian K, Tang CY, Chen LY, Zheng S, Zhao Y, Ma LS, Xu L, Fan LH, Yu JD, Tan HS, Sun YL, Shen LL, Lu Y, Liu Q, Liu Y, Xiong Y. Berberine Reverses Breast Cancer Multidrug Resistance Based on Fluorescence Pharmacokinetics In Vitro and In Vivo. ACS OMEGA 2021; 6:10645-10654. [PMID: 34056218 PMCID: PMC8153757 DOI: 10.1021/acsomega.0c06288] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/26/2020] [Accepted: 03/01/2021] [Indexed: 06/12/2023]
Abstract
Exploring the mechanism through which berberine (Ber) reverses the multidrug resistance (MDR) of breast cancer is of great importance. Herein, we used the methyl thiazolyl tetrazolium assay to determine the drug resistance and cytotoxicity of Ber and doxorubicin (DOX) alone or in combination on the breast cancer cell line MCF-7/DOXFluc. The results showed that Ber could synergistically enhance the inhibitory effect of DOX on tumor cell proliferation in vitro, and the optimal combination ratio was Ber/DOX = 2:1. Using a luciferase reporter assay system combined with the bioluminescence imaging technology, the efflux kinetics of d-luciferin potassium salt in MCF-7/DOXFluc cells treated with Ber in vivo was investigated. The results showed that Ber could significantly reduce the efflux of d-luciferin potassium salt in MCF-7/DOXFluc cells. In addition, western blot and immunohistochemistry experiments showed that the expression of P-glycoprotein (P-gp/ABCB1) and multidrug resistance protein 1 (MRP1/ABCC1) in MCF-7/DOXFluc cells was downregulated upon Ber treatment. Finally, high-performance liquid chromatography was used to investigate the effect of Ber on DOX tissue distribution in vivo, and the results showed that the uptake of DOX in tumor tissues increased significantly when combined with Ber (P < 0.05). Thus, the results illustrated that Ber can reverse MDR by inhibiting the efflux function of ATP-binding cassette transporters and downregulating their expression levels.
Collapse
Affiliation(s)
- Ke Qian
- Department
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou 311402, China
- Academy
of Chinese Medical Science, Zhejiang Chinese
Medical University, Hangzhou 310053, China
| | - Chao-yuan Tang
- Department
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou 311402, China
- Changxing
People’s Hospital of Zhejiang, Huzhou 313100, China
| | - Li-ying Chen
- Department
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou 311402, China
- Academy
of Chinese Medical Science, Zhejiang Chinese
Medical University, Hangzhou 310053, China
| | - Shuang Zheng
- Department
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou 311402, China
| | - Yue Zhao
- Department
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou 311402, China
- Academy
of Chinese Medical Science, Zhejiang Chinese
Medical University, Hangzhou 310053, China
| | - Li-sha Ma
- Department
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou 311402, China
- Academy
of Chinese Medical Science, Zhejiang Chinese
Medical University, Hangzhou 310053, China
| | - Li Xu
- The
First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China
| | - Lu-hui Fan
- Department
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou 311402, China
| | - Jian-dong Yu
- Department
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou 311402, China
| | - Hong-sheng Tan
- Hongqiao
International Institute of Medicine, Shanghai Tongren Hospital/Clinical
Research Institute, Shanghai Jiao Tong University
School of Medicine, Shanghai 200025, China
| | - Ya-lan Sun
- Department
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou 311402, China
| | - Li-li Shen
- Department
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou 311402, China
| | - Yang Lu
- Department
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou 311402, China
| | - Qi Liu
- Department
of Dermatology, Johns Hopkins University
School of Medicine, Baltimore, Maryland 21231, United States
| | - Yun Liu
- Division
of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School
of Pharmacy, University of North Carolina
at Chapel Hill, Chapel Hill 27599, North Carolina, United States
| | - Yang Xiong
- Department
of Pharmaceutical Sciences, Zhejiang Chinese
Medical University, Hangzhou 311402, China
- Academy
of Chinese Medical Science, Zhejiang Chinese
Medical University, Hangzhou 310053, China
| |
Collapse
|
3
|
Chen L, Chen Z, Zheng S, Fan L, Zhu L, Yu J, Tang C, Liu Q, Xiong Y. Study on mechanism of elemene reversing tumor multidrug resistance based on luminescence pharmacokinetics in tumor cells in vitro and in vivo. RSC Adv 2020; 10:34928-34937. [PMID: 35514396 PMCID: PMC9056898 DOI: 10.1039/d0ra00184h] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Accepted: 06/28/2020] [Indexed: 01/10/2023] Open
Abstract
While elemene (ELE) can reverse tumor multidrug resistance (MDR), the mechanisms for ELE reversing MDR remain unclear. Numerous studies have suggested that the efflux functionality of ATP-binding cassette (ABC) transporters, not their quantity, is more relevant to tumor MDR. However, no appropriate methods exist for real-time detection of the intracellular drug efflux caused by ABC transporters in vitro, especially in vivo, which hinders the examination of MDR reversal mechanisms. This study directly investigates the correlation between efflux functionality of ABC transporters and MDR reversal via ELE, using d-luciferin potassium salt (d-luc) as the chemotherapeutic substitute to study the intracellular drug efflux. Here, a luciferase reporter assay system combined with bioluminescence imaging confirmed that the efflux of d-luc from MCF-7/DOXFluc cells in vitro and in vivo was significantly reduced by ELE and when combined with Doxorubicin (DOX), ELE showed a synergistically anti-tumor effect in vitro and in vivo. Additionally, the luminescence pharmacokinetics of d-luc in MCF-7/DOXFluc cells and pharmacodynamics of the combined ELE and DOX in vivo showed a great correlation, implying that d-luc might be used as a probe to study ABC transporters-mediated efflux in order to explore mechanisms of traditional Chinese medicines reversing MDR.
Collapse
Affiliation(s)
- Liying Chen
- Department of Pharmaceutical Science, College of Pharmaceutical Science, Zhejiang Chinese Medical University Hangzhou 311400 Zhejiang China
| | - Zhi Chen
- Department of Pharmaceutical Science, College of Pharmaceutical Science, Zhejiang Chinese Medical University Hangzhou 311400 Zhejiang China
- The First People's Hospital of Jiande Jiande 311600 Zhejiang China
| | - Shuang Zheng
- Department of Pharmaceutical Science, College of Pharmaceutical Science, Zhejiang Chinese Medical University Hangzhou 311400 Zhejiang China
| | - Luhui Fan
- Department of Pharmaceutical Science, College of Pharmaceutical Science, Zhejiang Chinese Medical University Hangzhou 311400 Zhejiang China
| | - Lixin Zhu
- Department of Pharmaceutical Science, College of Pharmaceutical Science, Zhejiang Chinese Medical University Hangzhou 311400 Zhejiang China
- Zhejiang Institute for Food and Drug Control Hangzhou 310004 Zhejiang China
| | - Jiandong Yu
- Department of Pharmaceutical Science, College of Pharmaceutical Science, Zhejiang Chinese Medical University Hangzhou 311400 Zhejiang China
| | - Chaoyuan Tang
- Department of Pharmaceutical Science, College of Pharmaceutical Science, Zhejiang Chinese Medical University Hangzhou 311400 Zhejiang China
| | - Qi Liu
- Department of Dermatology, Johns Hopkins University School of Medicine Baltimore MD 21231 USA
| | - Yang Xiong
- Department of Pharmaceutical Science, College of Pharmaceutical Science, Zhejiang Chinese Medical University Hangzhou 311400 Zhejiang China
| |
Collapse
|
4
|
Abstract
The study of pathological processes is often limited to in vitro or ex vivo assays, while understanding pathogenesis of an infectious disease requires in vivo analysis. The use of pathogens, genetically modified to express with luminescent enzymes, combined to charge-coupled device (CCD) cameras, constitutes a major technological advance for assessing the course of infection in an intact, living host in real time and in a noninvasive way. This technology, also called bioluminescence imaging, detects the photons emitted from biological sources of light through animal tissues. Here, we describe the method we developed to monitor leptospirosis in a mouse model, by following in a spatiotemporal scale, the dissemination and spread of leptospires. These bacteria have been genetically modified to express the firefly luciferase, which produces light in the presence of the substrate D-luciferin. This useful and accessible technology facilitates the study of the kinetics of blood and tissue dissemination of live leptospires, and the pharmacological impact of treatments and host directed therapeutics.
Collapse
Affiliation(s)
- Frédérique Vernel-Pauillac
- Biology and Genetic of the Bacterial Cell Wall Unit, Innate Immunity and Leptospira Group, Institut Pasteur, Paris, France
| | - Catherine Werts
- Biology and Genetic of the Bacterial Cell Wall Unit, Innate Immunity and Leptospira Group, Institut Pasteur, Paris, France.
| |
Collapse
|
5
|
Coix Seed Extract Enhances the Anti-Pancreatic Cancer Efficacy of Gemcitabine through Regulating ABCB1- and ABCG2-Mediated Drug Efflux: A Bioluminescent Pharmacokinetic and Pharmacodynamic Study. Int J Mol Sci 2019; 20:ijms20215250. [PMID: 31652737 PMCID: PMC6862065 DOI: 10.3390/ijms20215250] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Revised: 10/18/2019] [Accepted: 10/21/2019] [Indexed: 01/29/2023] Open
Abstract
A deep insight into the function and kinetics of ATP-binding cassette (ABC) transporters may aid in the development of pharmaceutics that can minimize the particular facet of chemo-resistance. We utilized bioluminescence imaging to monitor the ABC transporter mediated intracellular drug efflux function. We also investigated the potential association between the intracellular bioluminescent pharmacokinetic profiles and the anti-tumor efficacy of the coix seed extract and gemcitabine against pancreatic cancer cells in vitro and in vivo. The bioluminescent pharmacokinetic parameters and pharmacodynamic index (IC50 and TGI) were determined. The expression levels ABCB1 and ABCG2 were assessed. Results showed that coix seed extract could synergistically enhance the anti-cancer efficacy of gemcitabine (p < 0.05). Meanwhile coix seed extract alone or in combination with gemcitabine could significantly increase the AUCluc while decreasing the Kluc (p < 0.01). Western blot and immunohistochemistry assay demonstrated that coix seed extract could significantly mitigate gemcitabine-induced upregulation of ABCB1 and ABCG2 protein. The Pearson correlation analysis demonstrated that the bioluminescent pharmacokinetic parameters and pharmacodynamic index have strong association in vitro and in vivo. In conclusion coix seed extract could augment the efficacy of gemcitabine therapy in pancreatic cancer cells may at least partly due to the alteration of ABC transporter-mediated drug efflux function.
Collapse
|
6
|
Synthesis of N-Peptide-6-Amino-d-Luciferin Conjugates with Optimized Fragment Condensation Strategy. Int J Pept Res Ther 2018. [DOI: 10.1007/s10989-018-9768-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Mann A, Han H, Eyal S. Imaging transporters: Transforming diagnostic and therapeutic development. Clin Pharmacol Ther 2016; 100:479-488. [PMID: 27327047 DOI: 10.1002/cpt.416] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2016] [Revised: 06/13/2016] [Accepted: 06/16/2016] [Indexed: 01/22/2023]
Abstract
Molecular imaging allows noninvasive assessment of drug distribution across pharmacological barriers. Thus, it plays an increasingly important role in efforts to understand the interactions of molecules with membrane transporters during drug development and in clinical pharmacology. We describe established and emerging imaging modalities utilized for studying transporter expression and function. We further present examples of how molecular imaging could provide insights into the contribution of transporters to drug disposition and effects.
Collapse
Affiliation(s)
- A Mann
- Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel
| | - H Han
- Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel
| | - S Eyal
- Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel. .,The David R. Bloom Centre for Pharmacy and Dr. Adolf and Klara Brettler Centre for Research in Molecular Pharmacology and Therapeutics at The Hebrew University of Jerusalem, Israel.
| |
Collapse
|
8
|
Khamenehfar A, Beischlag TV, Russell PJ, Ling MTP, Nelson C, Li PCH. Label-free isolation of a prostate cancer cell among blood cells and the single-cell measurement of drug accumulation using an integrated microfluidic chip. BIOMICROFLUIDICS 2015; 9:064104. [PMID: 26594265 PMCID: PMC4644147 DOI: 10.1063/1.4934715] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/14/2015] [Accepted: 10/14/2015] [Indexed: 05/12/2023]
Abstract
Circulating tumor cells (CTCs) are found in the blood of patients with cancer. Although these cells are rare, they can provide useful information for chemotherapy. However, isolation of these rare cells from blood is technically challenging because they are small in numbers. An integrated microfluidic chip, dubbed CTC chip, was designed and fabricated for conducting tumor cell isolation. As CTCs usually show multidrug resistance (MDR), the effect of MDR inhibitors on chemotherapeutic drug accumulation in the isolated single tumor cell is measured. As a model of CTC isolation, human prostate cancer cells were mixed with mouse blood cells and the label-free isolation of the tumor cells was conducted based on cell size difference. The major advantages of the CTC chip are the ability for fast cell isolation, followed by multiple rounds of single-cell measurements, suggesting a potential assay for detecting the drug responses based on the liquid biopsy of cancer patients.
Collapse
Affiliation(s)
- A Khamenehfar
- Department of Chemistry, Simon Fraser University , Burnaby, British Columbia V5A 1S6, Canada
| | - T V Beischlag
- Faculty of Health Sciences, Simon Fraser University , Burnaby, British Columbia V5A1S6, Canada
| | - P J Russell
- Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Department Faculty of Health, Queensland University of Technology , Princess Alexandra Hospital, Translational Research Institute, Brisbane, Australia
| | - M T P Ling
- Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Department Faculty of Health, Queensland University of Technology , Princess Alexandra Hospital, Translational Research Institute, Brisbane, Australia
| | - C Nelson
- Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Department Faculty of Health, Queensland University of Technology , Princess Alexandra Hospital, Translational Research Institute, Brisbane, Australia
| | - P C H Li
- Department of Chemistry, Simon Fraser University , Burnaby, British Columbia V5A 1S6, Canada
| |
Collapse
|
9
|
Mann A, Semenenko I, Meir M, Eyal S. Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes. AAPS JOURNAL 2015; 17:788-801. [PMID: 25823669 DOI: 10.1208/s12248-015-9752-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Accepted: 03/09/2015] [Indexed: 01/22/2023]
Abstract
Molecular imaging allows the non-invasive assessment of membrane transporter expression and function in living subjects. Such technologies have the potential to become diagnostic and prognostic tools, allowing detection, localization, and prediction of response of tumors and their metastases to therapy. Beyond tumors, imaging can also help understand the role of transporters in adverse drug effects and drug clearance. Here, we review molecular imaging technologies that monitor transporter-mediated processes. We emphasize emerging probe substrates and potential clinical applications of imaging the function of membrane transporters in cancer.
Collapse
Affiliation(s)
- Aniv Mann
- Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University, Room 613, Ein Kerem, Jerusalem, 91120, Israel
| | | | | | | |
Collapse
|
10
|
Patrick PS, Lyons SK, Rodrigues TB, Brindle KM. Oatp1 enhances bioluminescence by acting as a plasma membrane transporter for D-luciferin. Mol Imaging Biol 2014; 16:626-34. [PMID: 24798747 PMCID: PMC4161938 DOI: 10.1007/s11307-014-0741-4] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
PURPOSE Bioluminescence imaging is a powerful tool for studying gene expression and cell migration in intact living organisms. However, production of bioluminescence by cells transfected to express luciferase can be limited by the rate of plasma membrane transport of its substrate D-luciferin. We sought to identify a plasma membrane transporter for D-luciferin that could be expressed alongside luciferase to increase transmembrane flux of its substrate and thereby increase light output. PROCEDURES Luciferase-expressing cells were transfected with a lentivirus encoding the rat reno-hepatic organic anion transporter protein, Oatp1, which was identified as a potential transporter for D-luciferin. Light output was compared between cells expressing luciferase and those also expressing Oatp1. RESULTS In two cell lines and in mouse xenografts, co-expression of Oatp1 with luciferase increased light output by several fold, following addition of luciferin. CONCLUSIONS The increase in light output thus obtained will allow more sensitive detection of luciferase-expressing cells in vivo.
Collapse
Affiliation(s)
- P. Stephen Patrick
- Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge, UK CB2 1QW
- Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, UK CB2 0RE
| | - Scott K. Lyons
- Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, UK CB2 0RE
| | - Tiago B. Rodrigues
- Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, UK CB2 0RE
| | - Kevin M. Brindle
- Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge, UK CB2 1QW
- Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, UK CB2 0RE
| |
Collapse
|